In our study, we found that this PC-based regimen was extremely safe and effective in preventing neutralizing antibody production against our tumor-selective MEK inactivator in mice, allowing repeated use of our toxin in tumor therapy in immunocompetent mice. This evidence concerns the gene MAP2K7 and neoplasm.